Rapamycin also inhibits angiogenic responses in ErbB2 transgenic mouse mammary, human hepatocellular carcinoma, and in corneal neovascularization models [3,40-42] presumably by suppression of Akt-dependent HIF-1 signaling [3]. Here, ERBB2 is linked to hepatocellular carcinoma.